The Pharmaceutical Intellectual Property and Competition Law Review

The Pharmaceutical Intellectual Property and Competition Law Review provides a practical overview of pharmaceutical intellectual property issues, including patent linkage and exclusivities, and related competition concerns. With a focus on recent developments, it is a useful tool for managing global risks in this area – analysing the key elements of the relevant legal and regulatory regimes across major jurisdictions worldwide.

Our team of authors, Sally ShorthosePeter WillisChris de Mauny and Pieter Erasmus have written the UK chapter of this publication.
Read the full chapter here.
Written by
Sally Shorthose
Sally Shorthose
As one of Bird & Bird's most experienced intellectual property partners, specialising in transactional IP matters, I offer a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance.
Chris de Mauny
Chris de Mauny
I am a patent litigation specialist in London. I advise clients from a range of industries, particularly life sciences, but also hi-tech.
Pieter Erasmus
Pieter Erasmus
I am an associate in the Intellectual Property Group in London, with a focus on regulatory and commercial matters primarily in the life sciences and healthcare sectors. Having a keen interest in all things life sciences and healthcare, I specialise primarily in providing regulatory advice in relation to a broad range of regulatory matters in these fields, including pharmaceuticals, medical devices, general healthcare, data protection/privacy (within the healthcare space and otherwise), clinical trials, marketing and advertising of health products, etc. My experience also includes providing regulatory advice in the context of other topics, including films and publications, general commercial and corporate governance, advertising and consumer protection law (regarding health products and other products), cosmetics, foodstuffs, fertilizers, farm feeds, agricultural and stock remedies, and automotive regulation.
Peter Willis
Peter Willis
A partner in our Competition & EU Law practice group based in London, I bring over 25 years' experience of providing solutions for our clients in highly regulated and technically complex markets. My no-nonsense advice on the application of EU and national competition and regulatory rules includes advising on investigations by competition authorities and regulators, cartel leniency applications, sector enquiries, complaints and merger filings.

Related articles

China passed new amendments to the Drug Administration Law
By Alison Wong, Emma Ren, Yang Li On 26 August 2019, China's National People's Congress passed the final...
The US/China Trade Agreement: what could it mean for the Pharma Industry?
Following a long period of negotiation, Phase I of the US-China Trade Agreement was published on 15 January...
Investing in the future of cannabis in the UK – lessons from the German model
The excitement around the potential for the UK cannabis market – medicinal and nutritional – to continue...

Leave a comment

Cookie consent
We use analytics cookies to help us understand if our website is working well and to learn what content is most useful to visitors. We also use some cookies which are essential to make our website work. You can accept or reject our analytic cookies (including the collection of associated data) and change your mind at any time. Find out more in our Cookie Notice.